Fulcrum Therapeutics Announces CEO Transition
04 Enero 2023 - 6:01AM
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage
biopharmaceutical company focused on improving the lives of
patients with genetically defined rare diseases, today announced
that Robert J. Gould, Ph.D., former founding chief executive
officer of Fulcrum and a current member of the Board of Directors,
has been appointed interim chief executive officer, effective
January 3, 2023. Dr. Gould succeeds Bryan Stuart, who is
transitioning from his CEO role and the Board of Directors to
pursue other opportunities. Fulcrum’s Board of Directors has
initiated a search for a permanent CEO.
“On behalf of the Board, I want to thank Bryan for his
contributions to Fulcrum during a transformative time in the
company’s trajectory, in which the company demonstrated proof of
concept for FTX-6058, initiated a registrational trial in FSHD, and
solidified our financial position with multiple successful
financings. We are highly confident in the Fulcrum team’s ability
to continue advancing our mission and achieving our long-term goals
while executing on Fulcrum’s strategic priorities,” said Kate
Haviland, chair of Fulcrum’s Board of Directors. “Dr. Gould’s deep
leadership and industry experience, along with his history with
Fulcrum, will enable a seamless transition, ensuring continuity of
our leadership, mission, strategy, and culture. In addition to
being a seasoned executive, Robert played a key role in setting the
stage for Fulcrum’s ongoing achievements, leading Fulcrum through
its transition to the public markets and its evolution into a
clinical-stage company. Dr. Gould is ideally situated to lead
Fulcrum at this pivotal time and to ensure a smooth transition to a
new CEO following the completion of the search.”
“I am deeply committed to Fulcrum’s mission and look forward to
working with the talented executive team at Fulcrum as interim CEO
as we continue to advance our two key clinical programs and execute
on our corporate objectives,” said Dr. Gould. “2023 will be a key
year for Fulcrum, as we execute on our two clinical programs,
FTX-6058 for sickle cell disease and losmapimod for
facioscapulohumeral muscular dystrophy disorder.”
“I am proud of Fulcrum’s tremendous progress in the past few
years. We have built an extraordinary leadership team, made
significant advancements with all of our programs, and created a
strong financial position,” said Bryan Stuart. “I look forward to
Fulcrum continuing to deliver on the disease-modifying potential of
these therapies that can have an important impact on patients’
lives.”
Robert J. Gould has over 35 years of biopharmaceutical industry
and management experience. He served as founding president and
chief executive officer of Fulcrum Therapeutics from 2016 to 2021,
after which he remained a member of the Board of Directors. Before
Fulcrum, he served as president and CEO of Epizyme from 2010 to
2015. Previously, Dr. Gould served as director of novel
therapeutics at the Broad Institute of MIT and Harvard from 2006 to
2010. Before that, he spent more than 20 years at Merck in
leadership positions of increasing responsibility, culminating in
the role of vice president, licensing, and external research.
During his time at Merck, Robert was instrumental in advancing more
than 20 compounds from discovery into clinical development in
multiple therapeutic areas. Prior to joining industry, Dr. Gould
completed post-doctoral studies in neuropharmacology at Johns
Hopkins University. He earned a Ph.D. in biochemistry from the
University of Iowa and a B.S. in chemistry from Spring Arbor
University. In addition to his role as a member of Fulcrum’s Board
of Directors, he currently serves on the boards of HemoShear
Therapeutics, Turnstone Biologics, Faeth Therapeutics, and Rubedo
Life.
About Fulcrum TherapeuticsFulcrum Therapeutics
is a clinical-stage biopharmaceutical company focused on improving
the lives of patients with genetically defined rare diseases in
areas of high unmet medical need. Fulcrum’s two lead programs in
clinical development are losmapimod, a small molecule for the
treatment of facioscapulohumeral muscular dystrophy (FSHD), and
FTX-6058, a small molecule designed to increase expression of fetal
hemoglobin for the treatment of sickle cell disease (SCD) and other
hemoglobinopathies, including beta-thalassemia. Fulcrum’s
proprietary product engine, FulcrumSeek™, identifies drug targets
that can modulate gene expression to treat the known root cause of
gene mis-expression. For more information, visit www.fulcrumtx.com
and follow us on Twitter @FulcrumTx and LinkedIn.
Contact:
Investors:Stephanie AscherStern IR,
Inc.stephanie.ascher@sternir.com212-362-1200
Media:Dee SmithExecutive Director, Corporate Communications
Fulcrum Therapeutics, Inc.dsmith@fulcrumtx.com202-746-1324
Fulcrum Therapeutics (NASDAQ:FULC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Fulcrum Therapeutics (NASDAQ:FULC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024